TAMOXIFEN-ASSOCIATED ENDOMETRIAL PATHOLOGY AND POSSIBILITIES FOR ITS CORRECTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Tamoxifen is the most commonly used drug for the treatment of breast cancer with its known effects on hormone-susceptible tissues. Retrospective and observational studies have reported an increased risk for benign uterine lesions in tamoxifen-treated postmenopausal women. Tamoxifen may cause endocervical and endometrial polyps, proliferative endometrial changes, endometrial hyperplasia and cancer, and others. All the above necessitates a search for possible ways of preventing and treat-ing this pathology.

Full Text

Restricted Access

About the authors

I. O MAMIKONYAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: irulikjan@rambler.ru

S. E SARKISOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: 7341497@mail.ru

Sh. N SATTAROV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: docshuhrat@yahoo.com

M. A BOIKO

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: bma555@bk.ru

S. A GYURDZHYAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: medicjan@yandex.ru

References

  1. Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). М.: ФГУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России; 2012.
  2. Лейтис Н.А. Возможности использования эхографии и допплерометрии в качестве скрининговых методов исследования при патологии эндометрия у женщин в менопаузе: Автореф. дис.. канд. мед. наук. М.; 2005.
  3. Jones M.E., van Leeuwen F.E., Hoogendoorn W.E., Mourits M.J., Hollema H., van Boven H. et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012; 14(3): R91.
  4. Chia S.K., Wolff A.C. With maturity comes confidence: EBCTCG tamoxifen update. Lancet. 2011; 378(9793): 747-9.
  5. Schmidt D. Changes in the endometrium after tamoxifen therapy. Pathology. 2006; 27(1): 27-32.
  6. Runowicz C.D., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Ford L.G. et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am. J. Obstet. Gynecol. 2011; 205(6): 535; e1-5.
  7. Perez-Medina T., Salazar F.J., San-Frutos L., Rios M., Jimenez J.S., Troyano J. et al. Hysteroscopic dynamic assessment of the endometrium in patients treated with long-term tamoxifen. J. Minim. Invasive Gynecol. 2011; 18(3): 349-54.
  8. Negoita M., Terinte C., Mihailovici M.S. Tamoxifen and endometrial pathology. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010; 114(4): 1114-7.
  9. Dibi R.P., Zettler C.G., Pessini S.A., Ayub A.V., de Almeida S.B., da Silveira G.P. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Menopause. 2009; 16(2): 293-300.
  10. Берштейн Л.М. Гормональный канцерогенез. СПб.: Наука; 2000. 198с.
  11. Pickar J.H. The endometrium - from estrogens alone to TSECs. Climacteric. 2009; 12(6): 463-77.
  12. Эллиниди В.Н., Туркевич Е.А. К вопросу о морфогенезе рака тела матки. Вопросы онкологии. 1999; 45(2): 138-41.
  13. Харитонова Т.В. Рак тела матки. Современная онкология. 2000; 2(2): 44-8.
  14. Клюкина Л.Б., Ерохина О.А. Цитологическая диагностика заболеваний эндометрия с помощью решающего правила. Онкология. 2006; 3: 228-32.
  15. Атабекова Л.А., Виноградова Н.М., Шарапова Е.И., Бурков С.Г. Значение эхографии в комплексной диагностике гиперпластических процессов эндометрия в условиях поликлиники. Медицинский журнал: SonoAce-Ultrasound. 2006; 14.
  16. Стрижаков А.Н., Давыдов А.И. Гистерорезектоскопия. М.: Медицина; 1997.
  17. Costa-Paiva L., Godoy C.E.Jr., Antunes A.Jr., Caseiro J.D., Arthuso M., Pinto-Neto A.M. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause. 2011; 18(12): 1278-82.
  18. Tsikouras P., Liberis V., Galazios G, Grapsas X., Kantari P., Papageorgiou S. et al. TV sonographic assessment in postmenopausal women with bleeding. Eur. J. Gynaecol. Oncol. 2008; 29(1): 67-71.
  19. Salim S., Won H., Nesbitt-Hawes E., Campbell N., Abbott J. Diagnosis and management of endometrial polyps: a critical review of the literature. J. Minim. Invasive Gynecol. 2011; 18(5): 569-8.
  20. Yela D.A., Hidalgo S.R., Pereira K.C., Gabiatti J.R., Monteiro I.M. Comparative study of transvaginal sonography and outpatient hysteroscopy for the detection of intrauterine diseases. Acta Med. Port. 2011; 24(Suppl.2): 65-70.
  21. Elfayomy A.K., Habib F.A., Alkabalawy M.A. Role of hysteroscopy in the detection of endometrial pathologies in women presenting with postmenopausal bleeding and thickened endometrium. Arch. Gynecol. Obstet. 2012; 285(3): 839-43.
  22. Lopez D.M., Fernandez Y.G., Sanchez A.V., Alvarez M.I., Reynaldo M.I., Delgado R.C. Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer. Menopause. 2013; 20(1): 64-71.
  23. Нефедов В.П., Нефедов О.В., Боголюбова И.М. Роль диагностических биопсий эндометрия в гинекологической практике. Казанский медицинский журнал. 2008; 4: 494-7.
  24. Sendag F., Sahin C., Zeybek B., Terek M.C., Oztekin K., Bilgin O. Retrospective analysis of hysteroscopic findings in breast cancer patients having adjuvant tamoxifen treatment. Eur. J. Gynaecol. Oncol. 2010; 31(4): 415-7.
  25. Gao W.L., Zhang L.P., Feng L.M. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen. Chin. Med. J. (Engl.). 2011; 124(15): 2335-9.
  26. Sestak I., Cuzick J. Preventive therapy for breast cancer. Curr. Oncol. Rep. 2012; 14(6): 568-73.
  27. Cicinelli E., Pinto V., Tinelli R., Saliani N., De Leo V., Cianci A. Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study. Fertil. Steril. 2007; 88(3): 698-701.
  28. Chin J., Konje J.C., Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst. Rev. 2009; (4): CD007245.
  29. Gardner F.J., Konje J.C., Bell S.C., Abrams K.R., Brown L.J., Taylor D.J. et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol. Oncol. 2009; 114(3): 452-6.
  30. Chan S.S., Tam W.H., Yeo W., Yu M.M., Ng D.P., Wong A.W. et al. A randomised controlled trial of prophylactic levonorg-estrel intrauterine system in tamoxifen-treated women. Br. J. Obstet. Gynaecol. 2007; 114(12): 1510-5.
  31. Ewies A.A., Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet. Gynecol. Surv. 2012; 67(11): 726-33.
  32. Kucera E., Holub Z., Svobodova G. Laparoscopic oophorectomy either with or without hysterectomy for early breast cancer. Eur. J. Gynaecol. Oncol. 2007; 28(4): 294-6.
  33. Edris F., Vilos G.A., Al-Mubarak A., Ettler H.C., Hollett-Caines J., Abu-Rafea B. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. J. Minim. Invasive Gynecol. 2007; 14(1): 68-73.
  34. Ruan X., Neubauer H., Yang Y., Schneck H., Schultz S., Fehm T. et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. 2012; 15(5): 467-72.
  35. Obr A.E., Edwards D.P. The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol. Cell. Endocrinol. 2012; 357(1-2): 4-17.
  36. Takahashi W.H., Lopes R.G., Depes Dde B., Martins de Castello Branco H.K. Results of hysteroscopic endometrial ablation after five-year follow-up. Rev. Bras. Ginecol. Obstet. 2012; 34(2): 80-5.
  37. Саркисов С.Э., Хитрых О.В., Куковенко Е.М. Отдаленные результаты и оптимизация тактики лечения полипов эндометрия в постменопаузе. Акушерство и гинекология. 2009; 5: 44-8.
  38. Lethaby A., Hickey M., Garry R. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2005; (4): CD001501.
  39. Matteson K.A., Abed H., Wheeler T.L., Sung V.W., Rahn D.D., Schaffer J.I. et al. Society of Gynecologic Surgeons Systematic Review Group. A systematic review comparing hysterectomy with less-invasive treatments for abnormal uterine bleeding. J. Minim. Invasive Gynecol. 2012; 19(1): 13-28.
  40. B0e Engelsen I., Woie K., Hordnes K. Transcervical endometrial resection: long-term results of 390 procedures. Acta Obstet. Gynecol. Scand. 2006; 85(1): 82-7.
  41. Кирикова Ю.М. Эффективность аблации эндометрия при рецидивирующих гиперпластических процессах слизистой оболочки тела матки: Автореф. дис.. канд. мед. наук. М.; 2008.
  42. Gao W., Zhang L., Li W., Li J., Wang W., Zhao W. et al. Three-year follow-up results of polypectomy with endometrial ablation in the management of endometrial polyps associated with tamoxifen in Chinese women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 161(1): 62-5.
  43. Попов А.А., Баринова И.В., Чечнева М.А., Чаусова Н.А. Малоинвазивные методы лечения женщин с гиперпластическими процессами в эндометрии. Российский вестник акушера-гинеколога. 2007; 4: 50-3.
  44. Feng L., Wang E. The dinical observation of endometrial ablation for tamoxifen-stimulated endometrial benign lesions. J. Minim. Invasive Gynecol. 2007; 14(6, Suppl.): S45-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies